The much-anticipated drug by AstraZeneca that is said to treat a rare type of eye cancer failed in the final stage of clinical trial. The company, however, assures the public that other studies involving Selumetinib, the drug in question, will not be affected.
AstraZeneca Experimental Eye Cancer Drug Selumetinib Fails Late-Stage Trial
Tech Times - 22 Jul 2015 14:50
The much-anticipated drug by AstraZeneca that is said to treat a rare type of eye cancer failed in the final stage of clinical trial. The company, however, assures the public that other studies involving Selumetinib, the drug in question, will not be affected.
Share this Article
Recommended